New Method for Differentiating T-cells (SJ-18-0019)

St. Jude Reference #SJ-18-0019

Description

Researchers at St. Jude have invented a novel way to expand chimeric antigen receptor (CAR) T cells that work better for gene therapy. These T cells could form the basis of the next generation of CAR therapies that provide sustainable, superior antitumor activity.

Incorporating IL-12 in in vitro culture conditions results in the generation of stem cell memory (Tscm) cells, which possess an enhanced ability to eradicate tumors without reaching exhaustion.


Keywords

cer, immunology, chimeric antigen receptor (CAR), T cell, stem cell memory (Tscm) cells, epigenetic, IL-12, expansion


Granted Patents or Published Applications

Pending PCT, published as WO 2020/012331.


Related Scientific References

Knocking out specific gene prevents T-cell exhaustion, boosts CAR T-cell responses

Brooke Prinzing et al, Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity, Science Translational Medicine (2021). DOI: 10.1126/scitranslmed.abh0272


Licensing Opportunities

St. Jude is seeking a partner or partners to help develop this for use with therapies. Contact: chad.riggs@stjude.org

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.